ID
45513
Beschreibung
Principal Investigator: Sami N. Malek, MD, University of Michigan Department of Internal Medicine, Division of Hematology-Oncology, Ann Arbor, MI, USA MeSH: Lymphoma, Follicular,Lymphoma, Non-Hodgkin https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000729 A cohort of follicular lymphoma cases had tumor cells purified from tissue samples after informed consent using flow cytometry. DNA was extracted from the cells, and samples were subjected to solution-based exome capture using the Illumina TruSeq Exome Enrichment Kit and the Illumina HiSeq 2000 platform.
Link
Stichworte
Versionen (1)
- 13.12.22 13.12.22 - Simon Heim
Rechteinhaber
Sami N. Malek, MD, University of Michigan Department of Internal Medicine, Division of Hematology-Oncology, Ann Arbor, MI, USA
Hochgeladen am
13. Dezember 2022
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
dbGaP phs000729 Follicular Lymphoma 2013 - Malek
Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type of cancer, and method for tumor and normal cell purification of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- Subject ID, sample ID, and sample use variable obtained from participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- Subject ID, disease diagnosis, age onset, and sex of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type of cancer, and method for tumor and normal cell purification of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
Ähnliche Modelle
Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type of cancer, and method for tumor and normal cell purification of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- Subject ID, sample ID, and sample use variable obtained from participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- Subject ID, disease diagnosis, age onset, and sex of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type of cancer, and method for tumor and normal cell purification of participants with follicular lymphoma and involved in the "Solution-based exome capture and HiSeq2000-based massively parallel sequencing of Follicular Lymphoma" project.
C1299222 (UMLS CUI [1,2])
C1704788 (UMLS CUI [1,2])
C0007634 (UMLS CUI [1,3])
C0185115 (UMLS CUI [1,4])
C0012854 (UMLS CUI [1,5])
C0025663 (UMLS CUI [1,2])
C0027651 (UMLS CUI [1,3])
C1268443 (UMLS CUI [1,4])
C1998793 (UMLS CUI [1,5])